Q2 FY2026 · ended Jun 30, 2026 · Revenue $239,000, -53.9% YoY · Filed Aug 10, 2026
Insight Molecular Diagnostics Inc. (IMDX) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $239,000 and a net loss of $11.3 million. Free cash flow was -$10.0 million. As of Jun 30, 2026 it held $17.8 million in cash and investments and $2.4 million in total debt.
Revenue
$239,000
-53.9% vs year-ago quarter
Net income
$-11.26M
-15.6% vs year-ago quarter
Operating cash flow
$-9.27M
-50.1% vs year-ago quarter
Free cash flow
$-10.05M
-54.0% vs year-ago quarter
EPS
$-0.31
-3.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
32.72M
+14.3% vs year-ago quarter
Net cash
$15.31M
Q2 FY2026
Operating margin
-3011.9%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IMDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Nashville, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1642380
- Former names
- OncoCyte Corp (until Jun 17, 2025); Oncocyte Corp (until Jun 17, 2025)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $239,000 | $32,000 | $1.1M | $260,000 | $518,000 |
| Operating income | -$11.4M | -$4.4M | -$23.4M | -$11.0M | -$9.8M |
| Net income | -$11.3M | -$4.3M | -$23.0M | -$10.9M | -$9.7M |
| Diluted EPS | -$0.31 | -$0.12 | -$0.72 | -$0.34 | -$0.30 |
| Operating cash flow | -$9.3M | -$7.6M | -$5.5M | -$4.6M | -$6.2M |
| Free cash flow | -$10.0M | -$8.3M | -$7.0M | -$5.7M | -$6.5M |
| Total assets | $29.4M | $40.4M | $25.8M | $43.9M | $50.5M |
| Total liabilities | $50.7M | $51.1M | $57.2M | $53.1M | $49.4M |
| Stockholders' equity | -$21.3M | -$10.7M | -$31.5M | -$9.2M | $1.1M |
| Cash and investments | $17.8M | $28.2M | $11.6M | $18.7M | $24.3M |
| Total debt | $2.4M | $2.9M | $3.3M | $2.9M | $3.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 21, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 17, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
All 688 Insight Molecular Diagnostics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.